Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Frequently Asked Questions
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News

Navidea Appoints Jed Latkin as Interim Chief Operating Officer

Apr 26, 2016

Navidea and Macrophage Therapeutics to Provide Business Update

Apr 15, 2016

Navidea Updates Clinical Development Plan for Diagnostic Use of Lymphoseek® IV in Rheumatoid Arthritis

Apr 4, 2016

Navidea Announces Fourth Quarter and Full Year 2015 Results

Mar 23, 2016

Navidea Biopharmaceuticals to Announce Fourth Quarter and Full Year 2015 Results on March 23, 2016

Mar 21, 2016

Navidea Biopharmaceuticals Announces Delay in Filing of Form 10-K

Mar 14, 2016

Navidea and Platinum Enter Into Agreement Reaffirming Loan Obligations and Agreeing to Standstill Provisions

Mar 14, 2016

Immunotherapeutic Potential of Manoceptâ„¢ Platform Reviewed in the Journal Nuclear Medicine and Biology

Mar 10, 2016

Navidea Biopharmaceuticals Enrolls First Patient in Cervical Cancer Study of Lymphoseek®

Feb 11, 2016

Navidea Biopharmaceuticals to Present at 2016 BIO CEO & Investor Conference

Feb 4, 2016
    • 1...
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • ...37
    © 2021 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    Twitter linkedin Facebook
    Privacy Policy Disclaimer Sitemap